

FIG 1. Quenching of QS21 haemolytic activity with cholesterol




FIG. 2. Hydrolysis of QS21 in alkaline aqueous medium




FIG 3. Anti-gp120 CTL activity generated by QS21 as adjuvant




FIG 4. Anti-gp120 CTL activity generated by QS21 and cholesterol containing liposome as adjuvant





FIG 5. Anti-gD antibodies in AGM

FIG 6. Antigen specific proliferation was measured by stimulation in vitro with gD coupled to microbeads, and expressed as CPM of ^3H -TdR incorporated.





FIG 7. IL-2 production of cells after gD vaccination and restimulation in vitro.

FIG 8. Interferon gamma production of cells after gD vaccination and restimulation in vitro






FIG 9. RSV neutralisation titres and anti FG ELISA titres after vaccination

FIG 10. Comparison of QS21-SUV containing formulations with Alum formulation
Kinetics of the anti-HBs response (post I/II)




Figure 10 (continued)





FIG 11. Comparison of QS21-SUV containing formulations with Alum formulation Isotypic profile (post II) anti-HBs response



| | % IgG1 | % IgG2a | % IgG2b |
|-------------------------|--------|---------|---------|
| S,L* /Alum | 93 | 3 | 3 |
| S,L* /alum/MPL/QS21-SUV | 44 | 46 | 10 |
| S,L* /alum / QS21-SUV | 44 | 47 | 9 |
| S,L* /MPL /QS21-SUV | 27 | 55 | 18 |